The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
Braz. j. infect. dis
; 11(1): 174-175, Feb. 2007.
Artigo
em Inglês
| LILACS
| ID: lil-454700
Biblioteca responsável:
BR1.1
ABSTRACT
Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Temas:
Saúde do idoso
Base de dados:
LILACS
Assunto principal:
Crioglobulinemia
/
Fatores Imunológicos
/
Anticorpos Monoclonais
Idioma:
Inglês
Revista:
Braz. j. infect. dis
Assunto da revista:
Doenças Transmissíveis
Ano de publicação:
2007
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Sírio Libanês Hospital/BR
Similares
MEDLINE
...
LILACS
LIS